This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Coenzyme Q10 and statins

Authoring team

  • statins mechanism of action is inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA Reductase), the rate-limiting enzyme in the biosynthesis of cholesterol from acetyl-Coenzyme A via mevalonate and subsequent intermediates
    • inhibition of HMG CoA reductase also leads to a decrease the synthesis of nonsterol derivatives of mevalonate, including coenzyme Q10 (also known as ubiquinone)
    • studies have consistently shown that HMG CoA reductase inhibitors lower plasma coenzyme Q10 levels
  • coenzyme Q10
    • is an important redox component of the mitochondrial respiratory transport chain
      • role in the generation of high-energy products such as adenosine triphosphate (ATP)
      • ATP-bioavailability is a crucial factor regulating myocardial contractility
        • ATP-content correlating positively with systolic and diastolic left ventricular indices in diseased human myocardium
      • myocardial tissue levels of coenzyme Q10 are reduced in heart failure (1)
      • the reduced form of coenzyme Q10, is ubiquinol
        • ubiquinol is an antioxidant and free radical scavenger
      • vitamin E (a-tocopherol) and coenzyme Q10 are carried by LDL
  • coenzyme Q10 and statin treatment:
    • a study investigating the effect of treatment with simvastatin 20mg per day for a period of 6 months (2) showed
      • serum lipids showed the expected reductions.
      • plasma vitamin E and coenzyme Q10 levels were reduced by 17 ± 4% (P < 0·01) and 12 ± 4% (P < 0·03) at 6 months. However, the coenzyme Q10/LDL-cholesterol ratio and vitamin E/LDL-cholesterol ratio increased significantly
      • left ventricular ejection fraction (EF) decreased transiently after 1 month, while no significant change was observed at 3 and 6 months. Other markers of left ventricular function did not change significantly at any time point
      • the authors concluded that:
        • despite reduced plasma vitamin E and coenzyme Q10, 20 mg of simvastatin therapy is associated with a significantly increased coenzyme Q10/LDL-cholesterol ratio and vitamin E/LDL-cholesterol ratio
        • simvastatin treatment is not associated with impairment in left ventricular systolic or diastolic function in hypercholesterolaemic subjects after 6 months of treatment

Notes:

  • the transient reduction in a population with normal left ventricular ejection fraction was not associated with clinical evidence for reduced cardiac function (1)
  • in contrast to the findings of this single study statins have been shown to improve left ventricular function in several trials
    • atorvastatin therapy improved left ventricular ejection fraction in hypercholesteraemic patients with coronary artrey disease (CAD) by 13% after 2 years of treatment (3)
    • simvastatin has been shown to reduce the occurrence of heart failure in a cohort of CAD patients without previous evidence of congestive heart failure (4)
    • the improvement in cardiac function in heart failure in patients with CAD is perhaps not surpristing as it is most commonly owing to progression of coronary atherosclerosis and myocardial infarction – both of which are decreased by statin treatment

Reference:

  1. Folkers K et al. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985;82: 901–4.
  2. Colquhoun DM et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans. Eur J Clin Invest. 2005 Apr;35(4):251-8.
  3. Kontopoulos AG et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolemic patients. Curr Med Res Opin 2003;19: 22–7.
  4. Kjekshus J et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart Disease. J Card Fail 1997;3: 249–54.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.